Morgan J. MillerMorgan J.Miller

A multinational pharmaceutical company in connection with its global anti-corruption/FCPA due diligence associated with its US$16 billion acquisition of the vaccines business of another pharmaceutical company, divestiture of its oncology business and a consumer healthcare joint venture.

A Fortune 50 life sciences company in connection with corporate governance and enhancements to its global compliance program, including a global risk assessment, third-party training, internal audit program and third-party oversight.

A global specialist HIV company in conducting internal investigations of anti-corruption allegations in several countries, including in the CIS, Middle East and South America.

A foreign sovereign wealth fund in an investigation of certain trading activities by the SEC. The SEC declined to take enforcement action following a lengthy investigation.

A Fortune 50 medical device company in anti-corruption investigations by the SEC and Italian authorities. The SEC declined to institute enforcement action.

A major investment bank in an investigation by the SEC and state regulators regarding mortgage and securities-related issues.

A Fortune 50 company on anti-corruption matters in China, including with respect to a joint venture and third-party sales force.

A global oil and gas corporation in the successful resolution of investigations by the DOJ and SEC regarding possible FCPA violations in its Nigerian operations.

A global manufacturer in FCPA investigations by the SEC, including conducting internal investigations in China and Europe while developing a global risk assessment. The matter favorably resolved with the SEC, which credited the company’s response and remediation of the issues.

Counseling a private equity fund regarding compliance and due diligence matters in the Middle East.

Conducting an internal investigation of financial reporting issues for a national clothing manufacturer.

The audit committee of a major animal products company in conducting investigations of financial reporting, executive perquisites and potential conflicts of interest.

A CFO of a life sciences company in an investigation by the SEC regarding financial reporting. The SEC declined to take enforcement action.

Developing a global compliance program for a multinational technology company.

The former CFO of a NASDAQ-listed corporation in SEC and DOJ investigations concerning allegations of accounting fraud. Investigations concluded without any criminal charges or SEC enforcement proceedings.

Numerous other notable companies and executives in life sciences, technology, retail, telecommunications and manufacturing companies in investigations by the SEC regarding financial reporting, accounting, executive compensation and insider trading matters.

Conducting numerous internal investigations on behalf of corporations and their audit committees concerning accounting, revenue recognition, disclosure and various other securities-related issues.

Life sciences, technology and financial institutions and their officers and directors in shareholder class actions, derivative lawsuits and other commercial litigation, including Capital One Financial, Northwestern Corporation, Dura Pharmaceuticals, Ligand Pharmaceuticals and Semtech Corporation, among others.

Lawdragon